Journal
CYTOKINE
Volume 55, Issue 1, Pages 152-155Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.cyto.2011.03.014
Keywords
Cytokines; YKL-40; IL-6; TNF-alpha
Funding
- Commission of the European Communities [LSHM-CT-2004-005272 EXGENESIS]
- Danish Rheumatism Association
- Direktor Jens Aage Sorensen og Hustru Edith Ingeborg Sorensens Mindefond
- Danish National Research Foundation [DG 02-512-555]
- University of Copenhagen
- Faculties of Science and of Health Sciences at this University
Ask authors/readers for more resources
Plasma levels of YKL-40 are elevated in patients with systemic infection, inflammatory disorders and cancer. Both monocytes/macrophages, neutrophils, and cancer cells have the capacity to produce YKL-40, but the regulation during the inflammatory response is unknown. To study the possible role of interleukin-6 (IL-6) and tumor necrosis factor (TNF)-alpha in the regulation of YKL-40 plasma levels, we included healthy men, who received either recombinant human (rh)IL-6 (n = 6), rhTNF-alpha (n = 8) or vehicle (n = 7) for 3 h. The plasma levels of IL-6 and TNF-alpha reached similar to 150 and similar to 18 pg/ml, respectively, during the infusions. Following the IL-6 infusion, the plasma level of YKL-40 increased from similar to 30 to similar to 57 ng/ml (p < 0.05) at 24 h, and returned to normal values after 48 h. The plasma level of YKL-40 did not change during TNF-alpha infusion or infusion of vehicle. These data demonstrate that IL-6, but not TNF-alpha, has a key-role in the regulation of plasma YKL-40 levels during inflammation. (C) 2011 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available